Chimera Bioengineering
Melissa Fardy has a diverse work experience in the field of bioengineering and nanotechnologies. Melissa started their career as a Graduate Student Researcher at UC Berkeley and Lawrence Berkeley National Laboratory from July 2005 to December 2010. After that, they joined Svaya Nanotechnologies as a Member of Technical Staff from January 2011 to February 2013. Following that, they worked at Eve Biomedical, Inc. as a Staff Scientist from February 2013 to December 2015, and then as an Associate Director from December 2015 to February 2016. Currently, Melissa is with Chimera Bioengineering and has held multiple roles including Scientist from February 2016 to May 2019, Director of R&D from May 2019 to March 2022, and currently, they serve as the Associate Vice President of R&D since March 2022.
Melissa Fardy received their Bachelor of Science (BS) degree in Chemistry and Marine Science from the University of Miami. Melissa attended the university from 2001 to 2005. After completing their undergraduate studies, Melissa pursued further education. From 2005 to 2010, they attended the University of California, Berkeley, where they obtained their Ph.D. in Physical Chemistry.
This person is not in any teams
Chimera Bioengineering
They aspire to control the immune system. By the time a patient is sitting in front of an oncologist, cancer has evaded their immune system. Chimeric antigen receptor T-cells (CARs) are reprogrammed immune cells, hot-wired to circumvent immune-evasion. Clinical trials for CARs against liquid tumor cancers, like acute lymphoblastic leukemia andlymphoma, have shown transformative results for patients unresponsive to standard therapy.However, limited efficacy against solid tumor cancers, life-threatening toxicities, and limited persistence are impediments to these therapies making a wider impact on cancer patients.Chimera Bioengineering solves the challenges of CARs with drug-responsive gene regulators, which allow us to re-program the "software" of the immune system. They design CAR behavior that promises to minimize toxicity, maximize efficacy and extend persistence so that CARs can lead to cures.w